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Abstract Background Metallic stents change perma-
nently the mechanical properties of the vessel wall. How-
ever little is known about the implications of bioresorbable
vascular scaffolds (BVS) on the vessel wall strain. Methods
Patients (n = 53) implanted with an Absorb BVS that had
palpographic evaluation at any time point [before device
implantation, immediate after treatment, at short-term
(6–12 months) or mid-term follow-up (24–36 months)]
were included in the current analysis. The palpographic
data were used to estimate the mean of the maximum strain
values and the obtained measurements were classified
using the Rotterdam classification (ROC) score and
expressed as ROC/mm. Results Scaffold implantation led
to a significant decrease of the vessel wall strain in the
treated segment [0.35 (0.20, 0.38) vs. 0.19 (0.09, 0.29);
P = 0.005] but it did not affect the proximal and distal
edge. In patients who had serial palpographic examination
the vessel wall strain continued to decrease in the scaf-
folded segment at short-term [0.20 (0.12, 0.29) vs. 0.14
(0.08, 0.20); P = 0.048] and mid-term follow-up [0.20
(0.12, 0.29) vs. 0.15 (0.10, 0.19), P = 0.024]. No changes
were noted with time in the mechanical properties of the
vessel wall at the proximal and distal edge. Conclusions
Absorb BVS implantation results in a permanent alteration
of the mechanical properties of the vessel wall in the
treated segment. Long term follow-up data are needed in
order to examine the clinical implications of these findings.
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Introduction
Vessel wall mechanical behavior appears to be associated
with the compositional characteristics of the plaque and
predict future cardiovascular events [1–4]. Several studies
have shown that pharmaceutical or an interventional
treatment can influence the mechanical properties of the
vessel wall by altering its constituents [5–9]. Following an
endoluminal device implantation (i.e., a metallic stent or a
bioresorbable scaffold) the local vessel wall strain of the
implanted segment is reduced and this has been attributed
to the increased stiffness of the deployed device [5, 6, 9].
Recently we have reported the results of the palpo-
graphic analysis performed in segments implanted with the
updated revision of the Absorb bioresorbable vascular
scaffold (BVS) 1.1 [6]. We found that the vessel wall strain
is reduced in the scaffolded segments immediately after
device deployment but there are no further changes in the
mechanical properties of the vessel wall between post-
scaffold implantation and at short-term follow-up (i.e., at
6–12 months). The present analysis aims to investigate the
mid-term implications (i.e., at 24–36 months) of the
Absorb BVS 1.1 on the vessel wall strain.
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Methods
Included patients and study design
The ABSORB Cohort B trial (A Clinical Evaluation of the
Bioabsorbable Everolimus Eluting Coronary Stent System
the Treatment of Patients with de Novo Native Coronary
Artery Lesions) was a prospective multicenter single-arm
study designed to investigate the safety and efficacy of the
Absorb BVS 1.1 (Abbott Vascular, Santa Clara, CA, USA)
[10]. One hundred one patients were included in this study
and were divided in two groups (B1 and B2). The first
group had invasive imaging evaluation [i.e., coronary
angiography, grayscale intravascular ultrasound (IVUS),
IVUS virtual histology, palpographic and optical coherence
tomographic imaging] at baseline, 6 months and 2 years
follow-up; while the second group had the abovementioned
invasive tests at baseline, 1 year and at 3 years follow-up.
Optical coherence tomographic (OCT) examination was
optional and was not performed in all the studied patients.
The current analysis included only the patients who had a
palpographic assessment at least at one time point. The
Absorb Cohort B study was sponsored and financially
supported by Abbott Vascular.
The Absorb BVS 1.1 used in the ABSORB Cohort B
trial, is a fully bioresorbable device with dimensions
3.0 9 18 mm. The composition of the device consists of
poly-L-lactide (PLLA) that is covered by an thin layer of an
amorphous matrix of poly-D,L-lactide (PDLLA) which
contains and controls the release of the anti-proliferative
drug everolimus (concentration: 100 lg/cm2). The Absorb
BVS 1.1 has an in-phase zigzag hoops linked with bridges
design that provides the device increased radial strength
and eliminates the risk of late scaffold recoil, while the
polymer of this revision has been processed in such a way
so as to have a delayed degradation (by approximately
18 months comparing to the 1st revision).
The palpographic sub-study of the ABSORB Cohort B
trial had pre-specified hypotheses. In particular the inves-
tigators expected that the delayed degradation in Absorb
BVS 1.1 would result: either (1) in a delayed restoration of
the normal, pre-scaffold implantation, strain, or (2) it
would allow the built up of neointima tissue that would
permanently alter the mechanical properties of the vessel
wall.
IVUS acquisition and analysis
Intravascular ultrasound imaging was performed in the
treated artery using an Eagle Eye 20 MHz imaging catheter
(acquisition frame rate 30 frames/s, Volcano Corp, Rancho
Cordova, CA, USA) that was withdrawn with the use of an
automated pull-back device at a speed of 0.5 mm/s. During
IVUS examination the electrocardiogram and the aortic
pressure were recorded.
The radiofrequency IVUS imaging data were acquired
using a custom design workstation and were transferred to an
independent clinical research organization (Cardialysis,
Rotterdam, the Netherlands) for offline analysis. For each
studied artery the IVUS images portraying the 5 mm prox-
imal, the scaffolded, and the 5 mm distal segment were
analyzed. The local strain was estimated from the radiofre-
quency IVUS data using cross correlation analysis according
to a previously described methodology [11]. The measured
strain values were displayed in spread-out vessel plots using
a color coded map with the blue indicating low strain values
and the red/yellow a high strain (range 0–2 %) [11].
The strain values were classified according to the Rotter-
dam classification (ROC) score to four classes (ROC I:
0–0.5 %, ROC II: 0.6–\0.9 %, ROC III: 0.9–\1.2 % and
ROC IV:[1.2 %). A cross section was considered to have high
strain when the measured strain was classified as ROC III–IV
in an arc of[12. For each cross section the highest strain value
was recorded and considered as the strain of this section. The
mean of the maximum strain values measured in each segment
was determined and used to characterize the strain of the
segment. Results are presented as ROC/mm (Fig. 1).
Statistics
Continuous variables depending on their distribution are
presented as mean ± standard deviation or as median with
25th and 75th percentiles, as indicated in the tables. Cate-
gorical variables are presented as absolute values and per-
centages. Because of the small number of patients who had
palpographic evaluation at different time points we merged
the data from Cohort B1 and B2 and present our results at 4
time points: at baseline pre-scaffold implantation, immedi-
ately after scaffold implantation, at short-term (6–12 months),
and at mid-term follow-up (24–36 months). Comparison
between the two cohorts was done by t test and Chi square test,
or Fisher’s exact test when Cochran’s rule is not met.
Changes in the strain values between two different time
points were evaluated by means of paired Wilcoxon singed
rank test. A P value \0.05 (two-tailed) was considered
statistically significant. Data analysis was performed using
the SAS statistical computer package (SAS 9.2, SAS
Institute Inc., Cary, NC, USA).
Results
Studied population
Fifty-three from the 101 patients who were enrolled in the
Absorb Cohort B study had palpographic evaluation at
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least at one time point and included in this analysis. The
baseline characteristics of the studied population are shown
in Table 1. The patients that were enrolled in the Absorb
Cohort B1 group did not smoke and were more likely to
suffer from hypercholesterolemia and be admitted with
stable angina symptoms comparing to the subjects included
in the Absorb Cohort B2 group but otherwise there were
not significant differences in the baseline demographics
and angiographic characteristics between the two groups.
Palpographic evaluation
Only 14 patients had palpographic evaluation before scaf-
fold implantation, 44 patients had this investigation
immediate after device deployment, 41 at short-term, and
36 at mid-term follow-up. Twenty patients had serial pal-
pographic examination at the three time points (i.e., at
baseline immediate after scaffold deployment, at short-
term and mid-term follow-up).
For the entire study population (n = 53 patients) the strain
values did not change immediate after scaffold deployment
at the proximal and distal edge (Table 2). On the other hand
in the treated segment the strain decreased significantly after
device deployment. The vessel wall strain estimated at the
proximal edge at the two follow-up time points was not
different from the vessel wall strain before scaffold
deployment (P = 0.814 for the short-term follow-up and
P = 0.162 for the mid-term follow-up). However, when we
compared the follow-up values at the proximal edge with the
strain measured immediately after scaffold deployment we
found statistical significant differences (Table 2). At the
distal edge the strain values did not change with time.
The strain values in the scaffolded segment at the two
follow-up time points were considerably lower comparing
to baseline before device implantation (P = 0.002 for the
short-term and P = 0.001 for the mid-term follow-up) but
they were not different from these measured immediately
after scaffold deployment.
When we included in our analysis only the segments
(n = 20 patients) that had serial palpographic examination
(i.e., at baseline immediate after device deployment, at short-
term, and at mid-term follow-up) we found that the strain of
the proximal edge and distal edge did not change with time
(Table 3; Fig. 2). On the other hand in the scaffolded seg-
ment the strain values were significantly decreased at short-
and mid-term follow-up comparing to baseline.
Discussion
In this study we examined for the first time the implications
of the second revision Absorb BVS on the mechanical
Fig. 1 Snapshot showing the palpographic evaluation of a lesion
before scaffold implantation. Panel A shows a longitudinal IVUS
cross-section of the studied segment while panel B a spread out plot of
the measured vessel wall strain (the blue color indicates low strain
and the red/yellow high strain values). An IVUS cross section with the
estimated strain at the superficial plaque shown in color coding is
portrayed in panel C. Panel D shows the electrocardiogram, the
measured strain, and the blood pressure changes during the cardiac
circle throughout the pull-back of the catheter, whereas panel
E displays the strain values measured in the cross-section shown in
panel C. High strain was noted at 1 and 6 o’clock
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properties of the vessel wall. We found that in contrast to
the first generation which has a transient effect on vessel
wall strain, the updated revision Absorb BVS 1.1 causes a
permanent decrease of the strain values at the treated
segment without affecting the mechanical properties of the
proximal and distal edge [5, 6].
The reduction of the vessel wall strain noted immedi-
ately after Absorb BVS 1.0 or after Absorb BVS 1.1
deployment has been attributed to the shielding effect of
the device, and to fact that the foreign material is likely to
interfere with the palpographic estimations due to the
artifactual acoustic properties of the struts [5, 6, 12]. In the
first revision Absorb BVS the change in the strain values at
the treated vessel was temporary as at 6 months and
24 months follow-up the measured strain was increased
and approached the strain estimated before device
Table 1 Baseline demographics, angiographic characteristics and medications of the studied population
Patients’ demographics Absorb Cohort B Absorb Cohort B1 Absorb Cohort B2 P
N = 53 N = 20 N = 33
Age (years) 61.28 ± 8.41 63.84 ± 8.87 59.72 ± 7.85 0.096
Male 71.7 % (38/53) 75.0 % (15/20) 69.7 % (23/33) 0.678
Hypertension 67.3 % (35/52) 60.0 % (12/20) 71.9 % (23/32) 0.374
Hypercholesterolemia 83.0 % (44/53) 100.0 % (20/20) 72.7 % (24/33) 0.010
Diabetes 18.9 % (10/53) 15.0 % (3/20) 21.2 % (7/33) 0.725
Current smoking 15.1 % (8/53) 0.0 % (0/20) 24.2 % (8/33) 0.019
Prior PCI 22.6 % (12/53) 25.0 % (5/20) 21.2 % (7/33) 0.748
Stable angina 73.6 % (39/53) 90.0 % (18/20) 63.6 % (21/33) 0.035
Unstable angina 9.4 % (5/53) 5.0 % (1/20) 12.1 % (4/33) 0.639
Silent ischemia 1.9 % (1/53) 0.0 % (0/20) 3.0 % (1/33) 1.000
Treated vessel
Left anterior descending 47.2 % (25/53) 45.0 % (9/20) 48.5 % (16/33) 0.805
Left circumflex 24.5 % (13/53) 25.0 % (5/20) 24.2 % (8/33) 1.000
Right coronary artery 28.3 % (15/53) 30.0 % (6/20) 27.3 % (9/33) 0.831
QCA analysis pre-treatment
RVD (mm) 2.61 ± 0.34 2.60 ± 0.44 2.61 ± 0.28 0.949
MLD (mm) 1.04 ± 0.27 0.99 ± 0.31 1.07 ± 0.23 0.365
Diameter stenosis (%) 59.80 ± 9.96 61.25 ± 12.74 58.94 ± 7.98 0.482
Medications
b-blockers 73.6 % (39) 65.0 % (13) 78.8 % (26) 0.270
RAAS inhibitors 69.8 % (37) 65.0 % (13) 72.7 % (24) 0.443
Statins 94.3 % (50) 100.0 % (20) 90.9 % (30) 0.165
PCI percutaneous coronary intervention, QCA quantitative coronary angiography, RVD reference vessel diameter, MLD minimum luminal
diameter, RAAS renin angiotensin aldosterone system
Table 2 Strain values at the proximal edge, the scaffolded segment and the distal edge before device implantation, immediately after device
deployment, at short-term follow-up and at mid-term follow-up
Pre-scaffold
implantation (n = 14)
Post-scaffold
implantation (n = 44)
P1 Short term follow-
up (n = 41)
Mid-term follow-
up (n = 36)
P2 P3 P4
Proximal
edge
0.19 (0.13, 0.36) (12) 0.23 (0.10, 0.35) (29) 0.793 0.17 (0.12, 0.31)
(28)
0.15 (0.07, 0.20)
(19)
0.989 0.022 0.043
Scaffolded
segment
0.35 (0.20, 0.38) (14) 0.19 (0.09, 0.29) (44) 0.001 0.16 (0.12, 0.22)
(41)
0.15 (0.10, 0.20)
(36)
0.391 0.064 0.410
Distal edge 0.14 (0.08, 0.31) (9) 0.15 (0.06, 0.28) (28) 0.739 0.10 (0.04, 0.26)
(29)
0.19 (0.11, 0.26)
(25)
0.675 0.771 0.445
P1 denotes the significance of difference between the strain values estimated before and immediate after device implantation; P2 the significance
of difference between the strain values at post-scaffold implantation and at short-term follow-up; P3 the significance of difference between the
strain values at post-scaffold implantation and at mid-term follow-up; and P4 the significance of differences of the strain values at the two follow-
up time points
The number in the parenthesis at the left side of each column indicates the number of segments analyzed at each time point
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implantation [5, 6]. These findings were attributed to the
resorption process which was completed at 2 years follow-
up but also to the late recoil noted in the first revision [13,
14]. The latter argument is highlighted by the findings of
Tanimoto et al. [13] who showed that late scaffold recoil is
more intense at 6 months follow-up in the high-strain fibro-
necrotic plaques; thus it can be speculated that the late
recoil of the scaffold over these plaques may allow resto-
ration of their mechanical properties contributing to the
increased strain values noted at 6 and 24 months follow-up.
On the other hand in the second revision Absorb BVS
the polymer has been processed in such a way so as its
degradation to delay by approximately 18 months com-
paring to the first revision and the scaffold has a different
design which provides the device with a better radial
support [14]. These modifications prolong the mechanical
integrity of the scaffold resulting in a delayed restoration of
vessel vasomotion at 12 months follow-up, and eliminate
the risk of late recoil [15].
Furthermore, we have recently demonstrated that in
Absorb BVS 1.1 a thick layer of neointimal tissue develops
(mean thickness 210–220 lm at short-term follow-up) that
covers the entire circumference of the vessel shielding the
underlying plaque [16]. Histology studies in porcine
models have shown that the neointima tissue consists of
smooth muscles cells and fibrous tissue and thus the
superficial plaque is anticipated to exhibit low strain values
in a palpographic examination [2, 3, 17]. Indeed the strain
values reported in our analysis at short- and mid-term
follow-up are close to the strain measured in fibrotic pla-
ques by Korte et al. [3] using elastography in pig models. It
appears that the second revision Absorb BVS 1.1 modifies
permanent the mechanical properties of the superficial
plaque by altering its phenotype to a more stable form
(Fig. 3). Our findings indicate that in contrast to the
metallic stents, which are anticipated to have a similar
effect on the mechanical properties of the vessel wall, in
bioresorbable scaffolds minor changes in their design are
Table 3 Strain values at the proximal edge, the scaffolded segment
and the distal edge before device implantation, immediately after
device deployment, at short-term and at mid-term follow-up in
patients who had serial palpographic examination immediate after
scaffold implantation and at the two follow-up time points
Post-scaffold implantation
(n = 20)
Short term follow-up
(n = 20)
Mid-term follow-up
(n = 20)
P1 P2 P3
Proximal edge 0.25 (0.13, 0.33) (12) 0.15 (0.07, 0.23) (12) 0.16 (0.09, 0.22) (12) 0.278 0.135 0.817
Scaffolded
segment
0.20 (0.12, 0.29) (20) 0.14 (0.08, 0.20) (20) 0.15 (0.10, 0.19) (20) 0.048 0.024 0.922
Distal edge 0.11 (0.04, 0.23) (12) 0.11 (0.06, 0.31) (12) 0.20 (0.11, 0.24) (12) 0.880 0.874 0.692
P1 denotes the significance of difference between the strain values at post-scaffold implantation and at short-term follow-up; P2 the significance
of difference between the strain values at post-scaffold implantation and at mid-term follow-up; and P3 the significance of differences of the
strain values at the two follow-up time points
The number in the parenthesis at the left side of each column indicates the number of segments analyzed at each time point
Fig. 2 Changes in vessel wall
strain (ROC/mm) at the
proximal edge the scaffolded
segment and the distal edge in
patients who had serial
palpographic examination
immediately after scaffold
implantation at short-term and
mid-term follow-up. ROC
Rotterdam classification
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likely to have detrimental implications on vessel wall
strain. Thus the results of this analysis cannot be extrapo-
lated to other scaffolds even to these with a similar design
and composition.
The effect of the decreased strain on vessel wall path-
ophysiology is yet unknown. Several studies have dem-
onstrated that the ability of the vessel wall to expand as a
response to a pulsatile cyclic strain has an athero-protective
role as it stimulates eNOS gene regulation, promotes
prostacyclin synthesis and maintains the contractile phe-
notype of the smoothes muscles cells [18–20]. However,
plaques exhibiting low strain such as the pathological
intimal thickening appear stable and rarely cause future
events, while the plaques that demonstrate a high strain are
associated with increased vulnerability [1, 4, 21]. Therefore
it can be argued that the low strain estimated in stable
plaques is sufficient for the stimulation of the pulsatile
cyclic strain-dependent athero-protective mechanisms and
for triggering the necessary mechanotransduction and
pathophysiogical pathways that prevent plaque progres-
sion. In Absorb BVS this argument is supported by his-
tology studies showing that in scaffolded segments the
smooth muscles cells maintain their benign contractile
phenotype, and by clinical reports demonstrating
Fig. 3 Spread out plot of the vessel wall strain at baseline before
Absorb BVS implantation (Ai), immediate after scaffold deployment
(Bi), at short-term (Ci), and mid-term follow-up (Di). The blue color
indicates low strain values where the red/yellow a high strain. It is
apparent that the incidence of the high strain values decreased
immediate after scaffold deployment and it is even lower at short-and
mid-term follow-up. Panels Aii, Bii, Cii and Dii portray correspond-
ing IVUS cross-sections acquired at baseline before and immediate
after scaffold deployment, at short-term, and at mid-term follow-up
respectively. The position of these frames in the spread-out vessel
plots is indicated with a yellow line. High strain values are noted at
the shoulders of an echolucent plaque before scaffold implantation
(Aii), however immediate after device deployment the strain values
are low in the entire circumference of the lumen (Bii). OCT imaging
performed after scaffold deployment this time point (Biii) indicates
the presence of a lipid rich plaque (the correspondence between IVUS
and OCT is shown with an asterisk). The strain values remain low at
short- and mid-term follow-up in the IVUS cross-section (panels Cii
and Dii respectively). OCT performed at the follow-up time points
shows that neointima tissue has been developed that sealed the
underlying plaque. The mean thickness of the neointima tissue is
measured 150 lm at short-term and 220 lm at mid-term follow-up
(Supplementary figure)
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restoration of the endothelial dependent vasomotion at
1 year follow-up, suggesting a functionally normal endo-
thelium that is capable to respond to chemical and
mechanical stimuli [15, 22].
Although palpography appears unable to predict the
natural history of a high risk plaque there is robust evi-
dence to support that the mechanical properties of the
vessel wall provide useful prognostic information since
patients with high strain plaques are more likely to expe-
rience acute coronary events comparing to those with low
strain lesions [1, 4]. Furthermore, the Integrated Bio-
markers and Imaging Studies I and II have shown that an
aggressive pharmaceutical treatment reduces local strain
values, whereas the vShield Evaluated at Cardiac hospital
in Rotterdam for Investigation and Treatment of TCFA
(SECRITT) trial that implemented a self-expanding stent to
seal high risk plaques have demonstrated a significant
decrease of the strain values immediate after device
deployment [7–9]. Our results are similar to what has been
reported to metallic stents, showing that Absorb BVS 1.1
implantation changes permanently the mechanical proper-
ties of the vessel wall and stabilizes the plaque. However,
further palpographic data after the full resorption of the
BVS are needed to confirm this statement and further
research and robust data from randomized control trials are
required before advocating the use of these devices for the
invasive sealing of vulnerable, prone-to-rupture plaques
[16, 23, 24].
Limitations
A major limitation of the current study is the fact that a
considerable number of patients did not have serial pal-
pographic examination. Thus, we included all the data
that were available from each patient acknowledging the
fact that missing examinations can affect the reported
results. To confirm the findings of our initial analysis we
also performed a sub-analysis including the patients who
had truly serial examinations. Although the number of
patients in the sub-analysis was small the agreement noted
between the results of the initial analysis and the sub-
analysis with regards the scaffolded segment allows us to
report these findings with some certainty. Another limi-
tation of our analysis was the lack of a control group with
serial palpographic examination that would allow us to
compare the reported changes in the vessel wall stain in
the scaffolded segments with these in native untreated
arteries.
Unfortunately OCT was an optional examination in the
ABSORB Cohort B study and thus only very few patients
(n = 4) had serial palpographic and OCT assessment. Thus
we were unable to combine these data and examine the
association between the changes in the measured strain at
follow-up and the neointimal thickness as well as the effect
of the different plaque characteristics (i.e., composition of
the plaque, thickness of the fibrous tissue over calcific and
lipid tissue, extent of the lipid and calcific tissue, plaque
burden and eccentricity) on this relation [25, 26].
Conclusions
This study for the first time investigated the mid-term
implications of the second revision Absorb BVS on the
mechanical properties of the plaque. We found that in
contrast to the first revision where the strain values of the
treated segment change temporarily, in the second revision
the strain of the vessel wall gradually decreases with time.
Long-term clinical follow-up data and evidence from ran-
domized studies are required in order to examine the
clinical implications of these findings.
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